When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Xylitol is a 5-carbon sugar alcohol that has been shown to prevent caries when incorporated into chewing gum and reduce the incidence of acute otitis media when incorporated…
Scoring system developed by UCSD- and UCSF-led research teams may be able to predict an individual's likelihood (and age-specific risk) of developing AD.
Joseph Vassalotti, MD, Chief Medical Officer of the National Kidney Foundation, wants to remind physicians that urine testing to measure the albumin-to-creatinine ratio (ACR) isn’t done as frequently as…
